Raw Garden Introduces Sprout™ Vape, Pioneering Terpene-Safe Plastic for Cannabis Hardware
California's leading cannabis extract company finds a cleaner alternative to commonly used plastic for vape hardware after testing reveals potential health risks
SANTA BARBARA, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- Raw Garden, California's leader in clean cannabis for over a decade, has developed a Terpene-Safe solution for the all-new Sprout™ all-in-one cannabis vape. This breakthrough underscores Raw Garden's unwavering commitment to safety, quality, and sustainability while setting a new industry standard for safer vaping materials. Sprout™ is the latest addition to Raw Garden's lineup of clean, single-source cannabis products, which includes concentrates, infused pre-rolls, and vapes.
When Raw Garden's in-house testing revealed potential health risks from the interaction between their terpene-rich cannabis oils and PCTG — a plastic commonly used in vape hardware — they set out to find a safer alternative. Working with their manufacturing partner Ispire Technology, Inc. (NASDAQ: ISPR) they identified PA12, a durable, terpene-safe plastic that resists heat and prolonged exposure to cannabis oils without degrading.Despite having already produced 300,000 units, the two companies boldly decided to discard over $1 million in inventory rather than compromise consumer safety.
'We thoroughly test all our products above what is required, and our heat testing showed that PCTG plastic became cloudy and corroded when exposed to our cannabis oils and heat. We felt it was highly likely that this degradation could lead to plastic particles being inhaled,' said Thomas Martin, CEO of Raw Garden. 'The risk to our customers was too high, so we delayed the launch of Sprout until we found a safer solution.'
Beyond ensuring Spout's safety, Raw Garden is sharing its findings industry-wide. To promote safer vape technology, the company has opted not to patent this innovation, allowing other brands to adopt this safer material freely. They are also working with Ispire to create a consortium to work on vape safety through innovation. With this initiative, Raw Garden is not just improving its own products but pioneering a movement toward greater safety and transparency in the cannabis vaping industry.
About the Sprout™ Vape
Raw Garden's new Sprout™ vape is produced in small batches using hand-selected cannabis, ensuring each release meets the highest standards for flavor, quality, and purity. Made with 100% single-source cannabis—with no additives, fillers, or artificial flavors—every strain retains its natural terpenes, aromas, and cannabinoids, delivering a full-spectrum, true-to-plant experience.
Designed for convenience and portability, Sprout™ measures just 1.5' x 2.25', making it compact enough to fit in any pocket or palm. It also features an anti-clog design with an overflow chamber that pulls excess oil and vapor away from the mouthpiece, preventing buildup and blocked pulls. The chamber is made from terpene-safe PA12 plastic.
Sprout™ is available in two of Raw Garden's industry-leading formulations:
Live Sauce – For the full plant experience.
Refined Live Resin – For maximum THC potency
Sprout™ also offers three heat modes, fine-tuned by the Raw Garden team for optimal flavor and potency:
Low (2V): Peak flavor
Medium (2.3V): Balanced flavor and potency
High (2.6V): Strongest hit—ideal for experienced users
Sprout™ will be available at select California retailers starting March 8th. Raw Garden products can be found in over 800 retail locations throughout the state.
About Raw GardenRaw Garden has been the leading producer of clean cannabis in California for over fifteen years. Its products are made from 100% single-source cannabis flower—no additives, harsh chemicals, or artificial flavors—grown outdoors in sunny Central California. The company uses entirely organic, Clean Green-certified farming techniques and ECCO-certified practices and upholds the highest standards of transparency. All lab results are freely available at www.rawgarden.farm.
In 2024, Raw Garden became a co-founding member of ECCO, an independent organization that provides third-party testing and certification for compliance with safety, quality, and environmental standards. By earning ECCO certification, brands and retailers demonstrate their commitment to consumer safety, product excellence, and environmental responsibility.
Since 2015, Raw Garden has been Clean Green Certified, the world's leading cannabis certification. Since cannabis isn't federally recognized as an agricultural crop, this certification is the closest equivalent to organic standards.
About Ispire Technology Inc.Ispire is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis vaping products. The Company's operating subsidiaries own or license more than 400 patents worldwide. Ispire's branded e-cigarette products are marketed under the Aspire name and are sold worldwide (except in the U.S., People's Republic of China and Russia) primarily through its global distribution network. The Company also engages in original design manufacture (ODM) relationships with e-cigarette brands and retailers worldwide. The Company's cannabis products are marketed under the Ispire brand name primarily on an ODM basis to other cannabis vapor companies. Ispire sells its cannabis vaping hardware in the US, Europe and South Africa and it recently commenced marketing activities and customer engagement in Canada and Latin America. For more information, visit www.ispiretechnology.com or follow Ispire on Instagram, LinkedIn, Twitter and YouTube.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d0d7e582-46f7-4dca-920a-f4c438e03e82
A video accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/61a56628-01dd-4aaf-b84d-eac07427abe4
CONTACT: Media Contact: Raw Garden PR pr@rawgarden.farmSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
AIP Realty Trust Announces Non-Brokered Offering of Preferred Units and Provides Update on AllTrades Transaction and Concurrent Financing
Pursuant to the subscription agreements to be entered into between each subscriber and the Trust, each subscriber will be subject to, among other things (i) coattail provisions to be adhered to in the case of a potential transfer of Preferred Units and (ii) a covenant by the Trust to purchase the Preferred Units from the subscriber in the event that the Preferred Units are to convert pursuant to the designation, limitations, rights, privileges, restrictions and conditions attaching to the Preferred Units should a subscriber beneficially own, or exercise control or direction over that number of voting securities of the Trust which is greater than 9.9% of the total issued and outstanding voting securities of the Trust. Except as otherwise expressly provided in the Third Amended and Restated Declaration of Trust dated June 17, 2022 (the ' Declaration of Trust '), each Preferred Unit shall have the right to receive notice of and to attend any meetings of Trust's unitholders and to one vote for each Preferred Unit held. Holders of Preferred Units will also have the right to a proportionate share, in preference to the Units, of (i) all allocations (including allocations of income of the Trust), (ii) all advances or distributions of cash or other property (including amounts out of the income of the Trust or other amounts) and any other advances or distributions of a similar nature made in accordance with the Declaration of Trust; and (iii) the share of the Preferred Units in the remaining Trust assets on dissolution in accordance with the terms of the Declaration of Trust. Each Preferred Unit shall be convertible into one Unit at no additional cost, on the earlier of: (a) five (5) business days following the holder of such Preferred Units providing notice to the Trust of its intent to convert its Preferred Units; (b) the closing by the Trust of any merger, acquisition, plan of arrangement, restructuring, reverse take-over or other similar transaction involving the Trust; (c) at the option of the trustees of the Trust; and (d) April 30, 2027. The terms and conditions of the Preferred Units have been filed on the Trust's profile at . VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- AIP Realty Trust (the ' Trust ' or ' AIP ') (TSXV: AIP.U) is pleased to announce a non-brokered private placement (the ' Financing ') in which the Trust intends to issue up to 14,000,000 Preferred Units – Series B Convertible (each, a ' Preferred Unit '), at a price of US$0.50 per Preferred Unit for aggregate gross proceeds of up to US$7,000,000. Story Continues The net proceeds of the Financing will be used to fund the costs associated with the completion of AIP's proposed business combination (the 'AllTrades Transaction') with AllTrades Industrial Properties, LLC ('AllTrades') as previously disclosed by the Trust in a news release dated November 14, 2024, including costs related to audit fees, legal fees, preparation of necessary documentation for the AllTrades Transaction and due diligence costs. The Financing is being completed independent of the completion of the AllTrades Transaction with the funds being made available for AIP's use immediately upon closing thereof. Completion of the Financing remains subject to approval from the TSX Venture Exchange (the 'TSXV'). The Trust may pay finder's fees on a portion of the Financing, subject to compliance with the policies of the TSXV and applicable securities legislation. AllTrades Transaction Update The Trust is also pleased to provide an update on the progress of the AllTrades Transaction. As previously disclosed on November 14, 2024, the Trust, through its subsidiary AIP OP, LP, entered into a securities purchase agreement with 2024 ATIP, Inc. pursuant to which the Trust intends to acquire all of the issued and outstanding membership interests of AllTrades. In order to support the AllTrades Transaction and the purchase of the six completed AllTrades Serviced Industrial Business Suites, the Trust intends to complete a brokered private placement in which it will seek to raise aggregate gross proceeds of up to US$100,000,000 which will be used to finance the AllTrades Transaction purchase price, among other things. The Trust is currently engaged in advanced discussions with several leading banks who have shown interest in serving as lead investment banker of the syndicate to the Concurrent Financing. The transaction terms and ultimate structure of the Concurrent Financing remain under consideration and subject to negotiation with the syndicate members. Upon the entering into of an engagement letter with lead agent to the Concurrent Financing, the Trust will file and disseminate a news release disclosing the final terms. 'We are thrilled with the momentum we have on this transformative transaction with AllTrades,' said Leslie Wulf, Executive Chairman of the Trust. 'Our negotiations with the banks and the degree of interest we've received represent a crucial step towards securing the necessary financing to support our vision. We look forward to providing further updates as we continue to work diligently towards completing this transaction.' About AIP Realty Trust AIP Realty Trust is a real estate unit investment trust with a growing portfolio of AllTrades branded Service Industrial Business Suites ('SIBS') light industrial flex facilities focused on small businesses and the trades and services sectors in the U.S. These properties appeal to a diverse range of small space users, such as contractors, skilled trades, suppliers, repair services, last-mile providers, small businesses and assembly and distribution firms. They typically offer attractive fundamentals including low tenant turnover, stable cash flow and low capex intensity, as well as significant growth opportunities. With an initial focus on the Dallas-Fort Worth market, AIP plans to roll out this innovative property offering nationally. For more information, please visit For further information from the Trust, contact: Leslie Wulf Executive Chairman (214) 679-5263 Or Greg Vorwaller Chief Executive Officer (778) 918-8262 Cautionary Statement on Forward-Looking Information This news release contains statements which constitute 'forward-looking information' within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of AIP Realty Trust with respect to future business activities and operating performance. Forward-looking information is often identified by the words 'may', 'would', 'could', 'should', 'will', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' or similar expressions and includes information regarding the ability to obtain regulatory and unitholder approvals, the closing of the Financing and Concurrent Financing and aggregate proceeds to be raised thereunder, the use of proceeds to be raised under the Financing, negotiations with the agents regarding the particulars of the Concurrent Financing, the closing of the AllTrades Transaction and other factors. When or if used in this news release, the words 'anticipate', 'believe', 'estimate', 'expect', 'target', 'plan', 'forecast', 'may', 'schedule' and similar words or expressions identify forward-looking statements or information. These forward-looking statements or information may relate to proposed financing activity, proposed acquisitions, regulatory or government requirements or approvals, the reliability of third-party information and other factors or information. Such statements represent the Trust's current views with respect to future events and are necessarily based upon a number of assumptions and estimates that, while considered reasonable by the Trust, are inherently subject to significant business, economic, competitive, political and social risks, contingencies and uncertainties. Many factors, both known and unknown, could cause results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward- looking statements. The Trust does not intend, and do not assume any obligation, to update these forward-looking statements or information to reflect changes in assumptions or changes in circumstances or any other events affecting such statements and information other than as required by applicable laws, rules and regulations. The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this news release are made as of the date of this news release. AIP does not undertake to update any such forward- looking information whether as a result of new information, future events or otherwise, except as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release is not an offer of securities for sale in the United States. The securities may not be offered or sold in the United States absent registration or an exemption from registration under U.S. Securities Act of 1933, as amended (the 'U.S. Securities Act'). The Trust has not registered and will not register the securities under the U.S. Securities Act. The Trust does not intend to engage in a public offering of their securities in the United States. Source: AIP Realty Trust
Yahoo
21 minutes ago
- Yahoo
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ('Jupiter' or the 'Company'), a clinical-stage pharmaceutical company developing JOTROL™, a proprietary resveratrol-based platform, today announced the official commercial launch of Nugevia™, its consumer longevity product line. The launch represents a pivotal milestone in Jupiter's strategy to generate near-term revenue while maintaining momentum in its clinical pipeline. Nugevia's debut comes as global demand accelerates for scientifically validated wellness solutions that extend healthspan and enhance mental and metabolic resilience. Backed by over eight years of pharmaceutical development, powered by Jupiter's proprietary JOTROL™ micellar delivery technology, Nugevia products bring a clinical-grade standard to the nutraceutical space. 'The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,' said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. 'By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credibility.' A New Standard in Evidence-Based Supplementation Nugevia's first three formulations—targeting mitochondrial support, mental clarity, and "beauty from within"—will be sold via a direct-to-consumer (DTC) model starting in Q3 2025. Each product integrates JOTROL™, Jupiter's enhanced resveratrol formulation that demonstrated a 9x improvement in bioavailability during clinical trials. JOTROL™ is also the foundation of Jupiter's ongoing therapeutic programs in Parkinson's and Alzheimer's disease. Unlike typical single-ingredient supplements, Nugevia features precision-engineered "intelligent stacking" of synergistic compounds designed to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. 'We cracked the code on resveratrol's widely published issue with bioavailability, and now we're unlocking its potential beyond the clinic,' added Rosén. 'Consumers are seeking longevity solutions that are both credible and effective. Nugevia meets that demand.' Strategic Synergy with Core Pipeline The Nugevia launch adds a new dimension to Jupiter's value proposition as a dual-path company—advancing clinical-stage therapies for CNS disorders while monetizing its platform in the booming longevity market, projected to reach $8 trillion by 2030. The Company expects this initiative to provide a self-reinforcing commercial engine, with revenues from Nugevia supporting ongoing clinical trials and expanding its shareholder-aligned business model. 'Nugevia represents more than a product launch—it's a strategic engine for growth,' said Rosén. 'By leveraging our core science in a consumer format, we're creating a near-term revenue stream that supports our therapeutic pipeline and strengthens long-term shareholder value. It's smart capital allocation with real scientific impact.' A digital press kit, including high-resolution product imagery and key brand information, is available at . About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company's platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company's pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer's Disease, Parkinson's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS. More information may be found on the Company's website About JOTROL Resveratrol is one of the world's most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication. Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer's Disease trial, and Yui et al., Friedreich's Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer's Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL toward a Phase IIa trial in Parkinson's Disease. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations, including the Company's ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as 'approximates,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company's final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company's securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@
Yahoo
21 minutes ago
- Yahoo
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for AXS-14 (esreboxetine) for the management of fibromyalgia. The FDA states that upon preliminary review, it found that the NDA was not sufficiently complete to permit a substantive review. Specifically, the FDA does not consider the second of the two placebo-controlled trials in the submission to be adequate and well-controlled because its primary endpoint was at 8 weeks and it used a flexible-dose paradigm. The FDA indicated that the first of the two placebo-controlled trials in the submission, which utilized a 12-week endpoint and a fixed-dose paradigm, is adequate and well-controlled. The FDA did not raise any questions relating to the positive results of the studies, both of which met their primary endpoints. To address the FDA's feedback, Axsome will conduct an additional controlled trial, which will use a fixed-dose paradigm and a 12-week primary endpoint as requested by the FDA. Axsome anticipates initiating this trial in the fourth quarter of 2025. 'The clear feedback provided by the FDA's Division of Anesthesiology, Addiction Medicine, and Pain Medicine allows us to move expeditiously with the continued development of this important investigational medicine for the approximately 17 million patients in the U.S. living with fibromyalgia. We are well positioned to initiate a new controlled trial that will incorporate the FDA's feedback by the end of 2025,' said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. 'As highlighted in the FDA's Patient-Focused Drug Development Initiative report The Voice of the Patient: Fibromyalgia, patients with fibromyalgia experience debilitating widespread pain, fatigue, and functional impairment, and report living with constant stigmatization, anxiety, depression, and fear of ongoing or worsening symptoms. We are excited and motivated by the potential for AXS-14 to address this high unmet medical need for patients, as evidenced by the consistent efficacy demonstrated to date across a broad range of fibromyalgia symptoms, including significant improvements in pain, function, and fatigue, in the completed trials.' About AXS-14 AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Esreboxetine, the SS-enantiomer of reboxetine, is more potent and selective than racemic reboxetine. AXS-14 is an investigational drug product not approved by the FDA. About Fibromyalgia Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.1 Other symptoms of this disorder can include tingling in the hands and feet and headaches.1 Fibromyalgia has considerable detrimental effects on physical, emotional, social, and day-to-day functioning.1 Fibromyalgia is considered to be mediated mainly in the central nervous system. Approximately 17 million Americans, 90% of whom are women, are estimated to suffer from fibromyalgia.2 Treatment options for fibromyalgia are limited with only three pharmacologic treatments currently approved by the FDA. About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@ Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@ References: Matthew J. Bair, Erin E. Krebs. Fibromyalgia. Ann Intern Med. 2020;172:ITC33-ITC48. doi:10.7326/AITC202003030 Vincent A, et al. Prevalence of fibromyalgia: a population-based study in Olmsted County, Minnesota, utilizing the Rochester Epidemiology Project. Arthritis Care Res (Hoboken). 2013 May;65(5):786-92. doi: 10.1002/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
